AXSOME THERAPEUTICS INC's ticker is AXSM and the CUSIP is 05464T104. A total of 184 filers reported holding AXSOME THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2023 | $3,899,512 | +16.3% | 48,995 | +2.1% | 0.31% | +5.9% |
Q3 2023 | $3,354,371 | -2.7% | 47,995 | 0.0% | 0.29% | +2.1% |
Q2 2023 | $3,448,921 | +17.7% | 47,995 | +1.1% | 0.28% | +11.0% |
Q1 2023 | $2,929,492 | -20.0% | 47,495 | 0.0% | 0.26% | -23.2% |
Q4 2022 | $3,663,289 | +55.4% | 47,495 | -10.1% | 0.33% | +1.8% |
Q3 2022 | $2,358,000 | +16.5% | 52,845 | 0.0% | 0.33% | +24.4% |
Q2 2022 | $2,024,000 | -10.8% | 52,845 | -3.6% | 0.26% | +8.7% |
Q1 2022 | $2,270,000 | +43.6% | 54,845 | +31.1% | 0.24% | +52.5% |
Q4 2021 | $1,581,000 | +14.6% | 41,845 | 0.0% | 0.16% | +3.3% |
Q3 2021 | $1,379,000 | -17.7% | 41,845 | +68.4% | 0.15% | -16.4% |
Q2 2021 | $1,676,000 | +19.1% | 24,845 | 0.0% | 0.18% | +9.6% |
Q1 2021 | $1,407,000 | -31.9% | 24,845 | -2.0% | 0.17% | -35.8% |
Q4 2020 | $2,065,000 | +16.7% | 25,345 | +2.0% | 0.26% | +7.4% |
Q3 2020 | $1,770,000 | -13.4% | 24,845 | 0.0% | 0.24% | -19.3% |
Q2 2020 | $2,044,000 | +39.8% | 24,845 | 0.0% | 0.30% | +17.2% |
Q1 2020 | $1,462,000 | -59.9% | 24,845 | -29.5% | 0.26% | -49.7% |
Q4 2019 | $3,643,000 | +505.1% | 35,241 | +18.5% | 0.51% | +459.3% |
Q3 2019 | $602,000 | -20.1% | 29,741 | +1.7% | 0.09% | -18.0% |
Q2 2019 | $753,000 | +81.0% | 29,241 | 0.0% | 0.11% | +79.0% |
Q1 2019 | $416,000 | +407.3% | 29,241 | 0.0% | 0.06% | +342.9% |
Q4 2018 | $82,000 | -21.9% | 29,241 | -4.3% | 0.01% | -6.7% |
Q3 2018 | $105,000 | +28.0% | 30,551 | +19.6% | 0.02% | +15.4% |
Q2 2018 | $82,000 | +70.8% | 25,551 | +30.7% | 0.01% | +62.5% |
Q1 2018 | $48,000 | -56.0% | 19,551 | 0.0% | 0.01% | -52.9% |
Q4 2017 | $109,000 | 0.0% | 19,551 | 0.0% | 0.02% | -5.6% |
Q3 2017 | $109,000 | +0.9% | 19,551 | -0.5% | 0.02% | +5.9% |
Q2 2017 | $108,000 | +40.3% | 19,651 | 0.0% | 0.02% | +30.8% |
Q1 2017 | $77,000 | -42.1% | 19,651 | 0.0% | 0.01% | -45.8% |
Q4 2016 | $133,000 | +11.8% | 19,651 | +29.7% | 0.02% | +9.1% |
Q3 2016 | $119,000 | – | 15,151 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ALETHEA CAPITAL MANAGEMENT, LLC | 788,263 | $35,172,000 | 44.43% |
Fairmount Funds Management LLC | 1,896,647 | $84,628,000 | 14.88% |
ACT CAPITAL MANAGEMENT, LLC | 73,000 | $3,257,000 | 4.50% |
Ghost Tree Capital, LLC | 300,000 | $13,386,000 | 3.76% |
Ikarian Capital, LLC | 407,600 | $18,188,000 | 3.62% |
Paradigm Biocapital Advisors LP | 520,080 | $23,206,000 | 3.09% |
MORGAN JESS S & CO INC | 78,895 | $3,520,000 | 3.06% |
PFM Health Sciences, LP | 1,659,733 | $74,057,000 | 2.68% |
RTW INVESTMENTS, LP | 1,882,164 | $83,982,000 | 1.94% |
Ghost Tree Capital, LLC | 150,000 | $6,693,000 | 1.88% |